scholarly journals Antitumor agents. 258. Syntheses and evaluation of dietary antioxidant—taxoid conjugates as novel cytotoxic agents

2007 ◽  
Vol 17 (18) ◽  
pp. 5204-5209 ◽  
Author(s):  
Kyoko Nakagawa-Goto ◽  
Koji Yamada ◽  
Seikou Nakamura ◽  
Tzu-Hsuan Chen ◽  
Po-Cheng Chiang ◽  
...  
Keyword(s):  
Antitumor Agents ◽  
Cytotoxic Agents ◽  
Dietary Antioxidant

ChemInform Abstract: Antitumor Agents. Part 209. Pheophorbide-a Derivatives as Photo-Independent Cytotoxic Agents.

ChemInform ◽  
2010 ◽  
Vol 33 (20) ◽  
pp. no-no
Author(s):  
Prapai Wongsinkongman ◽  
Arnold Brossi ◽  
Hui-Kang Wang ◽  
Kenneth F. Bastow ◽  
Kuo-Hsiung Lee
Keyword(s):  
Antitumor Agents ◽  
Cytotoxic Agents ◽  
Pheophorbide A

scholarly journals Use of a Rapid Throughput In Vivo Screen To Investigate Inhibitors of Eukaryotic Topoisomerase II Enzymes

1998 ◽  
Vol 42 (4) ◽  
pp. 889-894 ◽  
Author(s):  
Timothy R. Hammonds ◽  
Anthony Maxwell ◽  
John R. Jenkins
Keyword(s):  
Topoisomerase Ii ◽  
Antitumor Agents ◽  
Viable Cell ◽  
Cytotoxic Agents ◽  
New Method ◽  
Temperature Sensitive ◽  
Cell Counts ◽  
Similar Drug ◽  
In Vivo Screen

ABSTRACT Topoisomerase II catalyzes the passage of one DNA helix through another via a transient double-stranded break. The essential nature of this enzyme in cell proliferation and its mechanism of action make it an ideal target for cytotoxic agents. Saccharomyces cerevisiae topoisomerase II has been frequently used as a model for testing potential inhibitors of eukaryotic topoisomerase II as antitumor agents. The standard in vivo method of estimating the sensitivity of S. cerevisiae to the antitopoisomerase drugs is via inhibition or kill curves which rely on viable-cell counts and is labor intensive. We present an alternative to this, a high-throughput in vivo screen. This method makes use of a drug-permeable S. cerevisiae strain lacking endogenous topoisomerase II, which is modified to express either human topoisomerase IIα or IIβ or S. cerevisiae topoisomerase II carried on plasmids. Each modified strain expresses a full-length topoisomerase II enzyme, as opposed to the more commonly used temperature-sensitive S. cerevisiae mutant expressing yeast or yeast/human hybrid enzymes. A comparison of this new method with a plating-and-counting method gave similar drug sensitivity results, with increased accuracy and reduced manual input for the new method. The information generated has highlighted the sensitivities of different topoisomerase II enzymes and isoenzymes to several different classes of topoisomerase II inhibitor.

scholarly journals Antitumor agents. 271: Total synthesis and evaluation of brazilein and analogs as anti-inflammatory and cytotoxic agents

2010 ◽  
Vol 20 (3) ◽  
pp. 1037-1039 ◽  
Author(s):  
Chiao-Ting Yen ◽  
Kyoko Nakagawa-Goto ◽  
Tsong-Long Hwang ◽  
Pei-Chi Wu ◽  
Susan L. Morris-Natschke ◽  
...  
Keyword(s):  
Total Synthesis ◽  
Antitumor Agents ◽  
Cytotoxic Agents ◽  
Anti Inflammatory

Antitumor agents. Part 209: Pheophorbide-a derivatives as photo-Independent cytotoxic agents

2002 ◽  
Vol 10 (3) ◽  
pp. 583-591 ◽  
Author(s):  
Prapai Wongsinkongman ◽  
Arnold Brossi ◽  
Hui-Kang Wang ◽  
Kenneth F. Bastow ◽  
Kuo-Hsiung Lee
Keyword(s):  
Antitumor Agents ◽  
Cytotoxic Agents ◽  
Pheophorbide A

Antitumor Agents, 129. Tannins and Related Compounds as Selective Cytotoxic Agents

1992 ◽  
Vol 55 (8) ◽  
pp. 1033-1043 ◽  
Author(s):  
Yoshiki Kashiwada ◽  
Gen-ichiro Nonaka ◽  
Itsuo Nishioka ◽  
Jer-Jang Chang ◽  
Kuo-Hsiung Lee
Keyword(s):  
Antitumor Agents ◽  
Cytotoxic Agents ◽  
Related Compounds

ChemInform Abstract: Antitumor Agents. Part 271. Total Synthesis and Evaluation of Brazilein and Analogues as Antiinflammatory and Cytotoxic Agents.

ChemInform ◽  
2010 ◽  
Vol 41 (39) ◽  
pp. no-no
Author(s):  
Chiao-Ting Yen ◽  
Kyoko Nakagawa-Goto ◽  
Tsong-Long Hwang ◽  
Pei-Chi Wu ◽  
Susan L. Morris-Natschke ◽  
...  
Keyword(s):  
Total Synthesis ◽  
Antitumor Agents ◽  
Cytotoxic Agents

scholarly journals Cardiac Toxicity of Cancer Chemotherapy

2017 ◽  
Vol 11 (1) ◽  
pp. 20
Author(s):  
Aarti Asnani ◽  
Randall T Peterson ◽  
◽  
Keyword(s):  
Antitumor Agents ◽  
Cardiac Toxicity ◽  
Survival Rates ◽  
Clinical Manifestations ◽  
Left Ventricular ◽  
Cytotoxic Agents ◽  
Cancer Therapies ◽  
Cancer Treatments ◽  
Number Of Patients ◽  
Increased Risk

With the aging of the population, the number of patients diagnosed with cancer has grown significantly over the past few decades. In parallel, survival rates have improved due to the increased efficacy and tolerability of cancer treatments. As such, the acute and long-term toxicities of cancer therapies have become increasingly prominent as contributors to morbidity and mortality in cancer survivors. Cardiac toxicity can occur with a broad range of cancer treatments, from conventional cytotoxic agents to newer targeted and immune-based therapies. Common manifestations of chemotherapy-associated cardiotoxicity include asymptomatic left ventricular dysfunction, congestive heart failure, myocardial ischemia, myocarditis, QT prolongation, and arrhythmia. In this review, we will describe antitumor agents that have commonly been associated with an increased risk of cardiac toxicity, with an emphasis on clinical manifestations, underlying mechanisms, and cardioprotective strategies that can be implemented in this setting.

The Potential Impacts of Tylophora Alkaloids and their Derivatives in Modulating Inflammation, Viral Infections, and Cancer

2019 ◽  
Vol 26 (25) ◽  
pp. 4709-4725 ◽  
Author(s):  
Duc-Hiep Bach ◽  
Sang Kook Lee
Keyword(s):  
Immune Modulation ◽  
Antitumor Agents ◽  
Viral Infections ◽  
Treatment Options ◽  
Current Treatment ◽  
Cytotoxic Agents ◽  
Targeted Agents ◽  
Cancer Treatments ◽  
New Era ◽  
Cancer Pathogenesis

Cancer chemotherapies or antitumor agents mainly remain the backbone of current treatment based on killing the rapidly dividing cancer cell such as tylophora alkaloids and their analogues which have also demonstrated anticancer potential through diverse biological pathways including regulation of the immune system. The introduction of durable clinically effective monoclonal antibodies, however, unmasked a new era of cancer immunotherapies. Therefore, the understanding of cancer pathogenesis will provide new possible treatment options, including cancer immunotherapy and targeted agents. Combining cytotoxic agents and immunotherapies may offer several unique advantages that are complementary to and potentially synergistic with biologic modalities. Herein, we highlight the dynamic mechanism of action of immune modulation in cancer and the immunological aspects of the orally active antitumor agents tylophora alkaloids and their analogues. We also suggest that future cancer treatments will rely on the development of combining tumor-targeted agents and biologic immunotherapies.

Sign in / Sign up

Export Citation Format

Share Document